Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4369MR)

This product GTTS-WQ4369MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4369MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14358MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ5287MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ11950MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ2282MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ9733MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ15753MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ3171MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ12539MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NV-01
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW